An interventional study of Standardized patient coaching in HR+/HER2- Early Breast Cancer, sponsored by Institut fuer Frauengesundheit. Recruiting at 8 sites in Germany. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Institut fuer Frauengesundheit · Not applicable, Interventional, and Supportive care
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit — 5 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut fuer Frauengesundheit.
Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, this one is one of 2 that started in 2026, is one of 2 with no phase, and was the 8th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit are open now, in 1 country. Recruiting first, the newest first:
Institut fuer Frauengesundheit · Sites in Germany
Ages 18+ · Women only
Institut fuer Frauengesundheit · Sites in Germany
Ages 18+
Institut fuer Frauengesundheit · Sites in Germany
Ages 18–60 · Women only
Institut fuer Frauengesundheit · Sites in Germany
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 257 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 183 across the 8 interventional studies, 1,600 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut fuer Frauengesundheit is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
1 of the studies in Breast Neoplasms by Institut fuer Frauengesundheit that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07531693Institut fuer FrauengesundheitPatient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.
The main question it aims to answer is, whether standardized coaching leads to patients taking abemaciclib much more consistently. Researchers will therefore compare therapy adherence of patients receiving standardized coaching to patients receiving routine care.
Participants will be asked to answer several questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive standardized coaching based on the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool© (MOATT)
Behavioral: Standardized patient coaching
Standardized patient coaching based on the Multinational Association of Supportive Care in Cancer (MASCC) Oral Agent Teaching Tool© (MOATT)
This study also gives AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Time to discontinuation
Time to permanent discontinuation of abemaciclib therapy
Time frame: From enrollment until 1 year or time of permanent discontinuation of abemaciclib, which ever comes first
Persistence rate
Abemaciclib persistence rate (defined as ongoing abemaciclib therapy)
Time frame: At 6 and 12 months after therapy start
Satisfaction with Information about Medicines Scale (SIMS-D)
This scale assess the patient´s knowledge about their treatment. The total score ranges from 0 to 17, with higher scores indicating a higher degree of overall satisfaction with information received.
Time frame: At 6 and 12 months after therapy start
Medication Adherence Rate Scale (MARS-D)
A total score ranges from 5 to 25 for adherence with higher scores indicating higher self-treported adherence.
Time frame: At 6 and 12 months after therapy start
Bloem's patient typology questionnaire
This 6-item instrument classifies patients into four segments: 1) High Acceptance / High Control (Active/Adjusted): Good mental, low care need. 2) Low Acceptance / High Control (Struggling/Active): High need for support to accept the situation. 3) High Acceptance / Low Control (Resigned/Passive): High need for educational/proactive support. 4) Low Acceptance / Low Control (Vulnerable/Anxious): Highest care need, requires intense supportive care.
Time frame: At 6 and 12 months after therapy start
Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 36 months is close to that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jun 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut fuer Frauengesundheit